GOVX

GeoVax Labs, Inc.

NasdaqCMUSDEQUITY DELAYED

0.64

▲ 0.04 (6.73%)

MARKET · —

Price

Open

0.64

Prev close

0.60

Day high

0.66

Day low

0.61

Volume

639.09K

Market cap

—

P/E (TTM)

—

52W range

0.59 – 20.00

Trailing performance

Price return · vs SPY

Returnvs SPY

-10.03% -8.7%

-23.10% -26.8%

-76.51% -79.6%

-57.78% -68.8%

YTD

-84.89% -97.2%

-96.60% -116.6%

-99.67% -173.8%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

0.68

-6.00% from price

SMA 20

0.71

-8.52% from price

SMA 50

0.97

-33.35% from price

SMA 100

1.28

-49.68% from price

SMA 200

3.18

-79.66% from price

EMA 12

0.68

-5.82% from price

EMA 26

0.78

-18.15% from price

EMA 50

0.98

-34.53% from price

RSI (14)

35.2

Neutral

MACD (12,26,9)

-0.10

Hist 0.01

ATR (14)

0.07

11.32% of price

Realised vol 30D

96.5%

Annualised

Bollinger upper

0.81

20, 2σ

Bollinger lower

0.60

20, 2σ

50 / 200 cross

Death

0.97 vs 3.18

Trend bias

Below 200

-79.66%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.86

More volatile than market

Correlation to SPY

0.17

Largely independent

Realised vol 30D

96.5%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-97.0%

Peak to trough

Max drawdown 5Y

-100.0%

Peak to trough

ATR 14

0.07

11.32% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 0.64

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

GOVX · links out to the publisher

GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit NewMediaWire · 2d ago GeoVax Highlights Capabilities Amid Congo's Expanding Ebola Outbreak NewMediaWire · 9d ago GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase NewMediaWire · 11d ago GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway Proactive · 12d ago GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study NewMediaWire · 16d ago GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio NewMediaWire · 19d ago GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update NewMediaWire · 26d ago GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy NewMediaWire · 32d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.